Liu Hong, Xu Yanbo, Ji Jiali, Dong Rongrong, Qiu Huiqing, Dai Xiaolan
Department of Medical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China.
Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China.
Oncol Lett. 2020 Mar;19(3):1947-1957. doi: 10.3892/ol.2020.11252. Epub 2020 Jan 7.
In order to compare the clinicopathological characteristics and survival outcomes of patients with ovarian clear cell carcinoma (CCC) to other epithelial cancer types, a total of 27,290 patients were analyzed, including 2,424 patients with CCC (8.9%), 3,505 patients with endometrioid cancer (EC) (12.8%), 2,379 patients with mucinous cancer (MC) (8.7%) and 18,982 patients with serous cancer (SC) (69.6%). Patients with EC had the most favorable prognosis and patients with SC had the poorest prognosis among all epithelial ovarian cancers. Among patients with stage I cancer, patients with CCC had a more favorable prognosis compared with patients with SC, especially after 60 months (landmark analysis results, HR=2.079, P=0.001) and had a poorer prognosis compared with patients with MC [restricted mean survival time (RMST) difference, -3.434 months]. Among patients at stages III and IV, patients with CCC had a poorer prognosis compared with patients with SC (RMST difference in stage III, -7.588 months; RMST difference in stage IV, -15.445 months) and had a more favorable prognosis compared with patients with MC (RMST difference in stage III, 10.850 months; RMST difference in stage IV, 8.430 months). The present results suggested that most patients with CCC exhibited, high grade, an early stage, unilateral status and were of a young age. In general, patients with SC presented the poorest prognosis among all patients with epithelial ovarian cancer and no significant survival difference was found between patients with CCC and MC. However, after adjusting for stage using pairwise comparisons, the prognosis of patients with CCC was found to be more favorable compared with the patients with SC and worse compared with patients with MC at stage I; the results at stage III-IV were opposite and the prognosis of patients with CCC was worse compared with the patients with SC and more favorable compared with the patients with MC.
为了比较卵巢透明细胞癌（CCC）患者与其他上皮癌类型患者的临床病理特征及生存结局，共分析了27290例患者，其中包括2424例CCC患者（8.9%）、3505例子宫内膜样癌（EC）患者（12.8%）、2379例黏液性癌（MC）患者（8.7%）和18982例浆液性癌（SC）患者（69.6%）。在所有上皮性卵巢癌中，EC患者的预后最有利，SC患者的预后最差。在I期癌症患者中，CCC患者的预后优于SC患者，尤其是在60个月后（标志性分析结果，HR = 2.079，P = 0.001），且与MC患者相比预后较差[限制平均生存时间（RMST）差异，-3.434个月]。在III期和IV期患者中，CCC患者与SC患者相比预后较差（III期RMST差异，-7.588个月；IV期RMST差异，-15.445个月），与MC患者相比预后更有利（III期RMST差异，10.850个月；IV期RMST差异，8.430个月）。目前的结果表明，大多数CCC患者表现为高级别、早期、单侧状态且年龄较轻。总体而言，SC患者在上皮性卵巢癌患者中预后最差，CCC患者和MC患者之间未发现显著的生存差异。然而，在使用成对比较调整分期后，发现I期时CCC患者的预后与SC患者相比更有利，与MC患者相比更差；III-IV期的结果相反，CCC患者的预后与SC患者相比更差，与MC患者相比更有利。
